BLRX קפיטליזציה חשבונאית biolinerx.com

BioLineRx Ltd. (BLRX) minimizes biopharmaceutical risks by combining the sale of certified drugs with the development of new clinical trials. The business relies on non-cyclical demand, as stem cell mobilization drugs remain independent of GDP growth rates. The price action, which stands at 0.02, is supported by stable logistics and long-term agreements with courier services that guarantee the uninterrupted delivery of therapy.

BioLineRx Ltd. is optimizing costs by delegating clinical trials to an external network of contractors to minimize fixed expenses. The dynamics of the company's equity on the balance sheet reflect the difference between all assets and liabilities, allowing investors to assess the real value of net assets and the stability of the organization's financial foundation under this specific outsourcing model.